ArticleFrontiers in bioengineering and biotechnology2026
Engaging U.S. experts in environmental oversight of GE crops as it relates to novel biotechnologies.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in agricultural biotechnologies, including gene editing and other new genomic techniques, are expanding the range of organisms, traits, and applications being released into the environment. Questions have been raised about the adequacy of the existing U.S. environmental governance frameworks. This study investigates U.S. expert stakeholder perspectives on the environmental oversight of genetically engineered crops and emerging biotechnologies using a qualitative methodology rooted in a systems-thinking approach. Semi-structured interviews were conducted with 16 experts in biotechnology oversight from industry, government, academia, and non-governmental organizations. Transcripts were analyzed thematically to identify perceptions related to strengths, limitations, and future needs of the oversight, especially in the wake of emerging technologies. Findings from the interviews indicate broad confidence in the scientific rigor and environmental safety for established genetic engineering applications, particularly in controlled agricultural contexts, contrary to the authors' initial expectations. At the same time, concerns were raised about the statutory limitations, regulatory burden, and the capacity of the current oversight system to evaluate more novel biotechnologies. Participants consistently emphasized recommendations for more centralized and proactive governance, risk-proportionate assessments, and adaptive management that is more grounded in the trait and impact of new agricultural biotechnologies. These findings highlight the importance of systems-oriented approaches for environmental oversight that supports innovation while protecting ecological sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.